Annexin reports first imaging-study results in Retinal Vein Occlusion

Annexin Pharmaceuticals AB (“Annexin”) provides an update on its ongoing clinical study in patients with Retinal Vein Occlusion (RVO) using fluorescent labelled ANXV. Images in a case-report of a patient with RVO indicates site-specific accumulation of ANXV in the vessels affected by retinal vein occlusion.

The release as fetched from its publisher. annexinpharma.com ↗